SCHEMBL2975715

SCHEMBL2975715

CS(=O)(=O)OCCN(CCI)c1cc(C(N)=O)c([N+](=O)[O-])cc1[N+](=O)[O-]

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.37
CYP3A4 P08684 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
HCAR3 P49019 2/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.32
THRB P10828 2/20 0.32
LMNA P02545 2/20 0.32
TDP1 Q9NUW8 1/20 0.31
ALDH3A1 P30838 1/20 0.31
VCAM1 P19320 1/20 0.31
MITF O75030 1/20 0.30
HTT P42858 1/20 0.30
CCR6 P51684 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2973810 0.94 MAPT (0.40) MAPTCYP3A4BLMPMP22HCAR3
SCHEMBL13338194 0.90 HCAR3 (0.45) MAPTCYP3A4BLMPMP22HCAR3
SCHEMBL2966410 0.89 MAPT (0.39) MAPTCYP3A4BLMPMP22HCAR3
SCHEMBL2970711 0.89 MAPT (0.37) MAPTCYP3A4BLMPMP22HCAR3
SCHEMBL8639061 0.86 MAPT (0.47) MAPTCYP3A4BLMPMP22HCAR3
SCHEMBL2969402 0.84 HCAR3 (0.43) HCAR3ALDH1A1KDM4ETHRBALDH3A1
SCHEMBL4080976 0.84 CYP3A4 (0.33) MAPTCYP3A4BLMPMP22HCAR3
SCHEMBL2966761 0.82 VCAM1 (0.43) MAPTHCAR3ALDH1A1KDM4ESMN1; SMN2
SCHEMBL3424399 0.82 ALDH1A1 (0.46) MAPTCYP3A4BLMPMP22HCAR3
SCHEMBL3418927 0.81 ALDH1A1 (0.43) MAPTCYP3A4BLMPMP22ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256191-A1 Nitroaniline-based alkylating agents and their use as prodrugs AUCKLAND UNISERVICES LIMITED (NZ) 2005-11-17 US claimed
US-7776924-B2 Nitroaniline-based alkylating agents and their use as prodrugs AUCKLAND UNISERVICES LIMITED (NZ) 2010-08-17 US disclosed
US-7776924-B2 Nitroaniline-based alkylating agents and their use as prodrugs AUCKLAND UNISERVICES LIMITED (NZ) 2010-08-17 US disclosed
US-20100121091-A1 Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-13 US disclosed
EP-2059499-A1 PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM Auckland Uniservices Limited (NZ) 2009-05-20 EP disclosed
WO-2008030112-A1 PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM AUCKLAND UNISERVICES LIMITED (NZ) 2008-03-13 WO disclosed
EP-1558568-A4 NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS AUCKLAND UNISERVICES LTD (NZ) 2006-10-18 EP disclosed
US-20050256191-A1 Nitroaniline-based alkylating agents and their use as prodrugs AUCKLAND UNISERVICES LIMITED (NZ) 2005-11-17 US disclosed
EP-1558568-A1 NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS Auckland Uniservices Limited (NZ) 2005-08-03 EP disclosed
WO-2004033415-A1 NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS AUCKLAND UNISERVICES LIMITED (NZ) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256191-A1 Nitroaniline-based alkylating agents and their use as prodrugs IDH3A, HIF1AN, IDH1 MAPT 4882/4885CYP3A4 317/4885BLM 4750/4885
US-20100121091-A1 Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom HRH2, HRH4, H1-2 MAPT 4882/4885CYP3A4 782/4885BLM 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.